DISPOSITION OF GABAPENTIN IN ANURIC SUBJECTS ON HEMODIALYSIS

被引:61
作者
WONG, MO
ELDON, MA
KEANE, WF
TURCK, D
BOCKBRADER, HN
UNDERWOOD, BA
SEDMAN, AJ
HALSTENSON, CE
机构
[1] HENNEPIN CTY MED CTR,DRUG EVALUAT UNIT,MINNEAPOLIS,MN 55404
[2] HENNEPIN CTY MED CTR,DEPT MED,DIV NEPHROL,MINNEAPOLIS,MN 55404
[3] UNIV MINNESOTA,COLL PHARM,MINNEAPOLIS,MN
[4] UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN
[5] WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,ANN ARBOR,MI
关键词
D O I
10.1002/j.1552-4604.1995.tb05020.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gabapentin is an anticonvulsant drug, which in man is cleared solely by renal excretion and is not bound to plasma proteins. Because the clearance of gabapentin is dependent on renal function, the pharmacokinetics of gabapentin were investigated in anuric subjects maintained on hemodialysis. Plasma samples were obtained over an 8-day period after administration of single oral 400-mg doses of gabapentin. Pre- and post-dialyzer plasma samples and dialysate samples from quantitative collection of dialyzer effluent were obtained during hemodialysis sessions performed 2, 4, and 7 days after dosing. A mean (SD) maximum gabapentin plasma concentration of 6.0 (2.4) mu g/mL was achieved at 4.7 (2.1) hours post-dose. The elimination half-life of gabapentin on non-hemodialysis days averaged 132 hours. Approximately 35% of the gabapentin dose was recovered in dialysate, and mean hemodialysis clearance of gabapentin was 142 (26) mL/min; approximately 93% of the dialyzer creatinine clearance. Gabapentin elimination half-life during hemodialysis was approximately 4 hours. Systemic plasma gabapentin concentrations increased approximately 30% during the first 2 hours after hemodialysis as a result of drug redistribution in the body. It is recommended that patients with end-stage renal disease maintained on hemodialysis receive an initial 300-mg to 400-mg gabapentin loading dose. Plasma gabapentin concentrations can be maintained by giving 200 to 300 mg of gabapentin after every 4 hours of hemodialysis.
引用
收藏
页码:622 / 626
页数:5
相关论文
共 12 条
[1]  
BARTOSZYK GD, 1986, CURRENT PROBLEMS EPI, V4, P147
[2]   PHARMACOKINETICS OF GABAPENTIN IN SUBJECTS WITH VARIOUS DEGREES OF RENAL-FUNCTION [J].
BLUM, RA ;
COMSTOCK, TJ ;
SICA, DA ;
SCHULTZ, RW ;
KELLER, E ;
REETZE, P ;
BOCKBRADER, H ;
TUERCK, D ;
BUSCH, JA ;
REECE, PA ;
SEDMAN, AJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (02) :154-159
[3]   GABAPENTIN AS AN ANTIEPILEPTIC DRUG IN MAN [J].
CRAWFORD, P ;
GHADIALI, E ;
LANE, R ;
BLUMHARDT, L ;
CHADWICK, D .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1987, 50 (06) :682-686
[4]   DETERMINATION OF GABAPENTIN IN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY AND PRE-COLUMN LABELING FOR ULTRAVIOLET DETECTION [J].
HENGY, H ;
KOLLE, EU .
JOURNAL OF CHROMATOGRAPHY, 1985, 341 (02) :473-478
[5]   THE EFFECT OF HEMODIALYSIS AND HEMOPERFUSION ON SERUM VALPROIC ACID CONCENTRATION [J].
KANDROTAS, RJ ;
LOVE, JM ;
GAL, P ;
OLES, KS .
NEUROLOGY, 1990, 40 (09) :1456-1458
[6]   CARBAMAZEPINE CLEARANCE IN HEMODIALYSIS AND HEMOPERFUSION [J].
KANDROTAS, RJ ;
OLES, KS ;
GAL, P ;
LOVE, JM .
DICP-THE ANNALS OF PHARMACOTHERAPY, 1989, 23 (02) :137-140
[7]   REMOVAL OF PHENYTOIN BY HEMODIALYSIS IN UREMIC PATIENTS [J].
MARTIN, E ;
GAMBERTOGLIO, JG ;
ADLER, DS ;
TOZER, TN ;
ROMAN, LA ;
GRAUSZ, H .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1977, 238 (16) :1750-1753
[8]  
SCHMIDT B, 1989, ANTIEPILEPTIC DRUGS, P295
[9]   DOUBLE-BLIND-STUDY OF GABAPENTIN IN THE TREATMENT OF PARTIAL SEIZURES [J].
SIVENIUS, J ;
KALVIAINEN, R ;
YLINEN, A ;
RIEKKINEN, P .
EPILEPSIA, 1991, 32 (04) :539-542
[10]  
VOLLMER KO, 1986, ARZNEIMITTEL-FORSCH, V36-1, P830